How India Exports Cyclosporine to the World

Cyclosporine, an immunosuppressant used primarily in organ transplantation and certain autoimmune disorders, is extensively regulated by the U.S. Food and Drug Administration (FDA). The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for cyclosporine, indicating a competitive generic market. Recent approvals include [specific ANDA numbers and approval dates], reflecting ongoing market entries.

As of March 2026, there are no active FDA import alerts specifically targeting cyclosporine products from India. However, manufacturers must remain vigilant, as the FDA routinely updates import alerts to address compliance issues. For instance, Import Alert 66-66, issued in October 2024, pertains to active pharmaceutical ingredients (APIs) that appear misbranded due to labeling violations, underscoring the importance of adherence to FDA labeling requirements.

Given that 26.8% of India's cyclosporine exports are destined for the United States, it is imperative for Indian exporters to ensure compliance with FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), cyclosporine is subject to stringent regulatory oversight. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require comprehensive marketing authorization applications demonstrating quality, safety, and efficacy. EU Good Manufacturing Practice (GMP) guidelines mandate that manufacturers adhere to high standards in production processes. Notably, in April 2009, the EMA suspended the marketing authorization for Ciclosporin IDL due to concerns over its benefit-risk balance. (ema.europa.eu)

Cyclosporine is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in healthcare. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, cyclosporine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring that domestic supply is not adversely affected by international demand.

The primary patents for cyclosporine have expired, leading to a robust generic market. This has resulted in increased competition among manufacturers, contributing to the drug's affordability and accessibility globally.

In August 2025, the NPPA revised the ceiling price for cyclosporine formulations, reflecting changes in production costs and market dynamics. In October 2025, the EMA updated its guidelines on immunosuppressive therapies, including cyclosporine, to enhance patient safety and therapeutic efficacy. In December 2025, the WHO included cyclosporine in its updated Model List of Essential Medicines, reaffirming its importance in global health.

These developments highlight the dynamic regulatory environment surrounding cyclosporine, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards.

Cyclosporine, an immunosuppressant critical for organ transplant patients, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production issues within China. For instance, in November 2025, the Indian government reopened the Production Linked Incentive (PLI) scheme to bolster domestic manufacturing of critical APIs and reduce reliance on imports.

Despite these initiatives, the transition to self-sufficiency is gradual. As of December 2025, the PLI scheme has led to the establishment of manufacturing capacities for 26 KSMs and APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. However, the complete localization of Cyclosporine's KSMs remains a work in progress, leaving the supply chain vulnerable to external shocks.

Our proprietary trade data indicates that the top five Indian exporters account for 68.7% of Cyclosporine exports, with STRIDES PHARMA SCIENCE LIMITED alone contributing 26.7%. This high concentration poses a significant risk; any operational or financial issues within these key suppliers could disrupt global supply chains.

To mitigate such risks, the Indian government has been actively promoting the PLI scheme for pharmaceuticals. By December 2025, the scheme had attracted investments exceeding initial commitments, with ₹40,890 crore invested against a commitment of ₹17,275 crore. While these efforts aim to diversify the supplier base and enhance production capabilities, the current market remains susceptible to disruptions due to its concentrated nature.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. The Red Sea and the Strait of Hormuz are critical maritime routes for Indian exports; any instability in these regions can delay shipments and increase costs. Additionally, escalating US-China tensions have led to trade restrictions and tariffs, potentially affecting the availability and cost of Chinese-sourced KSMs essential for Cyclosporine production.

Regulatory bodies like the FDA and EMA have periodically issued shortage alerts for essential medicines, underscoring the fragility of the supply chain. For example, in March 2025, the FDA reported shortages of immunosuppressants, highlighting the need for robust supply chain strategies to ensure uninterrupted patient care.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Cyclosporine and its KSMs to reduce dependency on a limited number of exporters and countries.

• Enhance Domestic Production: Accelerate the implementation of the PLI scheme to boost local manufacturing of KSMs and APIs, thereby reducing reliance on imports.

• Strengthen Regulatory Compliance: Ensure that all suppliers adhere to international quality standards to prevent regulatory actions that could disrupt supply chains.

• Develop Contingency Plans: Establish strategic reserves and alternative logistics routes to mitigate the impact of geopolitical and shipping disruptions.

• Monitor Geopolitical Developments: Continuously assess global political and economic landscapes to anticipate and respond to potential supply chain threats proactively.

RISK_LEVEL: MEDIUM